Latest Chinese Healthcare Reform Release Offers Little Change
This article was originally published in PharmAsia News
Executive Summary
According to an industry insider privy to China's healthcare reform draft soliciting the latest round of public opinion (PharmAsia News, Sep.15, 2008), the overall plan does not differ much from the previous version in terms of new concepts or changes. It seems to hammer together hodge-podge proposals from various organizations, with little specifics on execution and operation. Although the reform seeks to resolve the problem of "medical care sustained by drug income" through separate management of hospitals' income and expenses, the strategy does not address the fundamental issues. Current media only cover small portions of the entire plan as the opinion soliciting period will only be closed in about a month's time. (Click here for more - Chinese Language)
You may also be interested in...
China State Council Solicits Public Opinion Again For Healthcare Reform Plan
China's State Council has decided to solicit public opinion again to deepen its health care reform proposal. The draft spells out the reform's direction, objective, principles and key measures, with the overall goal of building up the basic healthcare system to cover both urban and rural residents by 2020. In the near term, the government will focus on five areas: (1) speeding up the guaranteed coverage of healthcare; (2) building a national basic medicine system; (3) completing health care service system at the primary level; (4) promoting uniform basic healthcare service; and (5) pushing reform pilots in public hospitals. A reform participant discloses that the proposal comprises a health reform framework and a complementary set of documents, with the latter detailing specific measures for implementation. (Click here for more - Chinese Language)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.